<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02750085</url>
  </required_header>
  <id_info>
    <org_study_id>myPKFiT™ Study</org_study_id>
    <nct_id>NCT02750085</nct_id>
  </id_info>
  <brief_title>Evaluation of a Simple Pharmacokinetic Tool (myPKFiT™) to Guide Personalized Factor VIII Dosing in Patients With Hemophilia</brief_title>
  <official_title>Evaluation of a Simple Pharmacokinetic Tool (myPKFiT™) to Guide Personalized Factor VIII Dosing in Patients With Hemophilia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Victor Blanchette</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>St. Paul's Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Montreal Children's Hospital of the MUHC</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Queen's University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University Hospital, Motol</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University Hospital Brno</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Royal Children's Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Sydney Children's Hospitals Network</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Royal Prince Alfred Hospital, Sydney, Australia</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>The Hospital for Sick Children</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is an investigator-initiated, industry-funded, multi-centre, international study that
      will be carried out prospectively at hemophilia treatment centres across Canada, the Czech
      Republic and Australia with SickKids as the coordinating site. The study will use a central
      laboratory not directly affiliated with any of the participating sites. Enrollment target is
      50 participants, both adult and pediatric with severe hemophilia A receiving Advate, who will
      each complete a 2-point and 6-point pharmacokinetic (PK) sampling. The main aim is to compare
      the results of a 2 sample PK using clinically practical time points and myPKFiT™ (a
      web-based, population PK Bayesian tool) to a 6 sample population PK to determine whether the
      results obtained are in good agreement.
    </textblock>
  </brief_summary>
  <overall_status>Enrolling by invitation</overall_status>
  <start_date>April 2016</start_date>
  <completion_date type="Anticipated">December 2018</completion_date>
  <primary_completion_date type="Anticipated">December 2018</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Terminal half-life (t1/2)</measure>
    <time_frame>2 years</time_frame>
    <description>2-point PK sampling protocol against 6-point PK sampling protocol</description>
  </primary_outcome>
  <primary_outcome>
    <measure>area under the plasma concentration versus time curve (AUC)</measure>
    <time_frame>2 years</time_frame>
    <description>2-point PK sampling protocol against 6-point PK sampling protocol</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Area under the moment curve (AUMC)</measure>
    <time_frame>2 years</time_frame>
    <description>2-point PK sampling protocol against 6-point PK sampling protocol</description>
  </primary_outcome>
  <primary_outcome>
    <measure>In vivo recovery (IVR)</measure>
    <time_frame>2 years</time_frame>
    <description>2-point PK sampling protocol against 6-point PK sampling protocol</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Maximum concentration (Cmax)</measure>
    <time_frame>2 years</time_frame>
    <description>2-point PK sampling protocol against 6-point PK sampling protocol</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Clearance (Cl)</measure>
    <time_frame>2 years</time_frame>
    <description>2-point PK sampling protocol against 6-point PK sampling protocol</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Volume of distribution at steady state (Vss)</measure>
    <time_frame>2 years</time_frame>
    <description>2-point PK sampling protocol against 6-point PK sampling protocol</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Mean residence time (MRT)</measure>
    <time_frame>2 years</time_frame>
    <description>2-point PK sampling protocol against 6-point PK sampling protocol</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Time to factor VIII concentration of 1% over baseline</measure>
    <time_frame>2 years</time_frame>
    <description>2-point PK sampling protocol against 6-point PK sampling protocol</description>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Hemophilia A</condition>
  <arm_group>
    <arm_group_label>2-point and 6-point PK sampling</arm_group_label>
  </arm_group>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Plasma collected from PK blood sampling
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with severe Hemophilia A
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Confirmed diagnosis of Hemophilia A;

          -  Severe disease (FVIII &lt;2%);

          -  Receiving ADVATE for prevention of bleeding (prophylaxis) or receiving ADVATE on
             demand and a candidate for prophylaxis;

          -  Body weight ≤120 kg; and ≥12kg;

        Exclusion Criteria:

          -  FVIII inhibitor positive (level of ≥0.6 Bethesda Units [BU] per mL using the Nijmegen
             modification of the Bethesda assay). Inhibitor status to be documented as negative
             prior to study enrollment according to the two most recent, consecutive inhibitor
             assays on record. If patients have &lt; 50 exposure days, an assay will be completed
             centrally within a reasonable timeframe (approximately 8 weeks suggested) to make sure
             that they are negative.

          -  Body weight &gt;120 kg or &lt;12kg;

          -  Human immunodeficiency virus (HIV) positivity with cluster of differentiation 4 (CD4)
             count &lt; 200 / microliter;

          -  Significant hepatic dysfunction, alanine aminotransferase (ALT) or aspartate
             aminotransferase (AST) &gt;5 times upper limit of normal

          -  History of recent events that might affect FVIII half-life (e.g., infection, surgery
             or an invasive procedure) within 2 weeks of blood sampling.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Victor S Blanchette, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>The Hospital for Sick Children</affiliation>
  </overall_official>
  <verification_date>April 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 7, 2016</study_first_submitted>
  <study_first_submitted_qc>April 20, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 25, 2016</study_first_posted>
  <last_update_submitted>April 17, 2018</last_update_submitted>
  <last_update_submitted_qc>April 17, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 18, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>The Hospital for Sick Children</investigator_affiliation>
    <investigator_full_name>Victor Blanchette</investigator_full_name>
    <investigator_title>Medical Director, Pediatric Thrombosis and Hemostasis Program</investigator_title>
  </responsible_party>
  <keyword>Hemophilia A</keyword>
  <keyword>pharmacokinetics</keyword>
  <keyword>myPKFiT</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hemophilia A</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Factor VIII</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

